| 0.689 0.095 (15.99%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.94 | 1-year : | 1.22 |
| Resists | First : | 0.81 | Second : | 1.04 |
| Pivot price | 0.61 |
|||
| Supports | First : | 0.42 | Second : | 0.35 |
| MAs | MA(5) : | 0.61 |
MA(20) : | 0.58 |
| MA(100) : | 0.61 |
MA(250) : | 0.78  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 31.1 |
D(3) : | 30.5 |
| RSI | RSI(14): 54.5 |
|||
| 52-week | High : | 2.03 | Low : | 0.42 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ BFRG ] has closed below upper band by 43.1%. Bollinger Bands are 178.6% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 9 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 0.63 - 0.63 | 0.63 - 0.63 |
| Low: | 0.58 - 0.58 | 0.58 - 0.59 |
| Close: | 0.59 - 0.59 | 0.59 - 0.6 |
BullFrog AI Holdings, Inc., along with its affiliated entities, functions as an advanced digital biopharmaceutical firm. Its core mission involves harnessing artificial intelligence and machine learning (AI/ML) to process and interpret extensive medical and healthcare datasets specifically within the United States. A central offering is bfLEAP, a proprietary AI/ML platform meticulously crafted for the thorough examination of both preclinical and clinical research data. The company has also secured critical intellectual property through licensing agreements. One such accord, with George Washington University, provides rights to utilize siRNA targeting Beta2-spectrin. This technology is being investigated for its therapeutic potential across a spectrum of human conditions, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease (NAFLD), and non-alcoholic steatohepatitis (NASH). Additionally, a partnership with Johns Hopkins University grants access to a distinct Mebendazole formulation, developed for the treatment of various human cancers or neoplastic diseases. Founded in 2017, BullFrog AI Holdings, Inc. operates from its headquarters in Gaithersburg, Maryland.
Wed, 23 Sep 2026
Bullfrog AI CEO Vininder Singh buys $44,917 in company stock By Investing.com - Investing.com Canada
Wed, 23 Sep 2026
Bullfrog AI CFO Joshua Blacher buys $26,425 in company stock - Investing.com
Wed, 23 Sep 2026
Bullfrog AI CEO Vininder Singh buys $44,917 in company stock By Investing.com - Investing.com South Africa
Wed, 23 Sep 2026
BullFrog AI Stock Surges Wednesday: What's Happening? - TradingView
Tue, 22 Sep 2026
BullFrog AI (BFRG) CFO buys 50,000 shares in open-market trades - Stock Titan
Tue, 22 Sep 2026
BullFrog AI (BFRG) chief buys 75,000 shares in open-market trade - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 19 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 13.1 (%) |
| Held by Institutions | 6.3 (%) |
| Shares Short | 97 (K) |
| Shares Short P.Month | 120 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.37 |
| Profit Margin | 0 % |
| Operating Margin | -658.9 % |
| Return on Assets (ttm) | -72.3 % |
| Return on Equity (ttm) | -130.8 % |
| Qtrly Rev. Growth | 547.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.01 |
| EBITDA (p.s.) | -0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -1.42 |
| PEG Ratio | 0 |
| Price to Book value | 1.71 |
| Price to Sales | 40.34 |
| Price to Cash Flow | -2.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|